Atai Life Sciences N.V. (NQ: ATAI )

15.25 USD +0.08 (+0.53%)

Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2021 Add to My Watchlist

Price and Volume

Volume	356,361
Open	15.00
Bid (Size)	14.91 (4)
Ask (Size)	16.99 (1)
Prev. Close	15.17
Today's Range	14.02 - 15.31
52wk Range	12.12 - 22.91
Shares Outstanding	N/A
Dividend Yield	39.34%

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals

October 12, 2021

Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028

October 11, 2021

Performance

YTD	-21.59%	-21.59%
1 Month	-6.73%	-6.73%
3 Month	-12.26%	-12.26%
6 Month	-21.59%	-21.59%
1 Year	-21.59%	-21.59%

More News

Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered

September 28, 2021

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

September 21, 2021

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs

September 30, 2021

What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders

October 11, 2021

Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021

October 15, 2021

Atai Life Launches Depression-Focused Firm

October 11, 2021

Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases

September 27, 2021

Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery

October 11, 2021

Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations

October 12, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.